GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (FRA:47N0) » Definitions » Issuance of Stock

Citius Pharmaceuticals (FRA:47N0) Issuance of Stock : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Citius Pharmaceuticals Issuance of Stock?

Citius Pharmaceuticals's Issuance of Stock for the three months ended in Jun. 2024 was €0.00 Mil.

Citius Pharmaceuticals's Issuance of Stock for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Citius Pharmaceuticals Issuance of Stock Historical Data

The historical data trend for Citius Pharmaceuticals's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Issuance of Stock Chart

Citius Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.10 13.23 76.02 - 12.93

Citius Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Citius Pharmaceuticals Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Pharmaceuticals Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (FRA:47N0) » Definitions » Issuance of Stock
Comparable Companies
PBYI TALS XFOR TNYA CARM ANNX TRVI BTAI XBIT INMB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CTXR:USA
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Website
https://www.citiuspharma.com
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Citius Pharmaceuticals Headlines

No Headlines